ALVO ▲ +0.6% - Alvotech $ALVO ALVO ALVO.IC - Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations Alvotech gained 0.6% following news that the FDA has accepted its Biologics License Application for AVT80, a subcutaneous biosimilar candidate for Entyvio®. The acceptance for review represents progress in the company's biosimilar development pipeline and signals that the application meets initial regulatory requirements for evaluation. This expansion of Alvotech's proposed Entyvio® program into subcutaneous formulations could open an additional market opportunity if approved. 31-AUG-2026 04:30 AM ET